Lenalidomide Sandoz 2.5 Mg Hard Capsules (Lenalidomide)

Lenalidomide binds to the cereblon component of the CRL4‑E3 ubiquitin ligase complex, leading to targeted degradation of the transcription factors Ikaros and Aiolos. This action modifies the immune micro‑environment, suppresses angiogenesis, and directly inhibits the proliferation of malignant plasma cells, thereby exerting its antineoplastic effect.

The specific dose of lenalidomide is individualized by the treating physician based on the patient’s diagnosis, disease stage, renal function, and prior therapies. Prescribers select the appropriate strength and schedule, which may be adjusted over the course of treatment according to clinical response and laboratory monitoring.

Lenalidomide is classified as contraindicated in pregnancy because of the potential for fetal harm, and its safety during breastfeeding has not been established. Women of childbearing potential must use effective contraception before, during, and after therapy, and the drug should not be used by nursing mothers.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and assistance with import documentation.

Lenalidomide is a second‑generation immunomodulatory drug that generally offers a more favorable safety profile than thalidomide, with lower rates of peripheral neuropathy and constipation. Compared with pomalidomide, lenalidomide is often used earlier in therapy and at lower potency, while pomalidomide may be reserved for patients who have progressed after lenalidomide‑based regimens.

Store the capsules at temperatures below 25 °C in their original blister pack, protecting them from moisture, heat and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the capsules appear discoloured.

Lenalidomide is taken orally as a hard capsule, usually with or without food as directed by the prescriber. The capsule should be swallowed whole with a glass of water and not crushed, chewed, or opened, to ensure consistent absorption.

The most serious adverse events include venous thromboembolism, severe cutaneous reactions such as Stevens‑Johnson syndrome, and the development of secondary primary malignancies. Patients should be monitored closely for signs of blood clots, skin rash, or unexplained symptoms and report them promptly to their healthcare provider.

Lenalidomide should not be used by individuals who are pregnant, have uncontrolled infections, or have a known hypersensitivity to lenalidomide or any component of the formulation. Caution is also advised in patients with severe renal impairment, uncontrolled cardiovascular disease, or a history of thromboembolic events.